Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

Javid J Moslehi¹, Joe-Elie Salem², Jeffrey A Sosman³, Bénédicte Lebrun-Vignes⁴, Douglas B Johnson⁵

Affiliations

¹ Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
² Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, UMR ICAN 1166, Sorbonne Universités, UPMC Univ Paris 06, Faculty of Medicine, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France.
³ Department of Medicine and Robert H Lurie Cancer Center, Northwestern University, Chicago, IL, USA.
⁴ AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, UMR ICAN 1166, Sorbonne Universités, UPMC Univ Paris 06, Faculty of Medicine, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France.
⁵ Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address: douglas.b.johnson@vanderbilt.edu.

PMID: 29536852
PMCID: PMC6668330
DOI: 10.1016/S0140-6736(18)30533-6

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

Javid J Moslehi et al. Lancet. 2018.

. 2018 Mar 10;391(10124):933.

doi: 10.1016/S0140-6736(18)30533-6.

Authors

Javid J Moslehi¹, Joe-Elie Salem², Jeffrey A Sosman³, Bénédicte Lebrun-Vignes⁴, Douglas B Johnson⁵

Affiliations

¹ Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
² Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, UMR ICAN 1166, Sorbonne Universités, UPMC Univ Paris 06, Faculty of Medicine, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France.
³ Department of Medicine and Robert H Lurie Cancer Center, Northwestern University, Chicago, IL, USA.
⁴ AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, UMR ICAN 1166, Sorbonne Universités, UPMC Univ Paris 06, Faculty of Medicine, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France.
⁵ Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address: douglas.b.johnson@vanderbilt.edu.

PMID: 29536852
PMCID: PMC6668330
DOI: 10.1016/S0140-6736(18)30533-6

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: JM has served as a consultant to Novartis, Pfizer, Bristol Myers Squibb, Pharmacyclics, Regeneron, Daiichi Sankyo, and Heat Biologics. DBJ serves on advisory boards for Bristol Myers Squibb, Genoptix, Incyte, Merck, and Novartis.

Comment in

Checkpoint Inhibitors May Induce Myocarditis.
[No authors listed] [No authors listed] Cancer Discov. 2018 May;8(5):OF3. doi: 10.1158/2159-8290.CD-NB2018-034. Epub 2018 Mar 23. Cancer Discov. 2018. PMID: 29572231
Reporting of immune checkpoint inhibitor-associated myocarditis.
Al-Kindi SG, Oliveira GH. Al-Kindi SG, et al. Lancet. 2018 Aug 4;392(10145):382-383. doi: 10.1016/S0140-6736(18)31542-3. Lancet. 2018. PMID: 30102167 No abstract available.
Reporting of immune checkpoint inhibitor-associated myocarditis.
Raschi E, Diemberger I, Poluzzi E, De Ponti F. Raschi E, et al. Lancet. 2018 Aug 4;392(10145):383. doi: 10.1016/S0140-6736(18)31549-6. Lancet. 2018. PMID: 30102168 No abstract available.
Reporting of immune checkpoint inhibitor-associated myocarditis.
Noseda R, Magro L, Stathis A, Ceschi A. Noseda R, et al. Lancet. 2018 Aug 4;392(10145):383-384. doi: 10.1016/S0140-6736(18)31557-5. Lancet. 2018. PMID: 30102169 No abstract available.

References

1. Wolchok JD. PD-1 Blockers. Cell 2015; 162(5): 937. - PubMed
1. Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. The New England journal of medicine 2016; 375(18): 1749–55. - PMC - PubMed
1. Heinzerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. Journal for immunotherapy of cancer 2016; 4: 50. - PMC - PubMed
1. Escudier M, Cautela J, Malissen N, et al. Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. Circulation 2017; 136(21): 2085–7. - PubMed
1. Lindquist M VigiBase, the WHO Global ICSR Database System: Basic Facts. Drug Inf J 2008; 42(5): 409–19.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- ClinicalTrials.gov

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

Affiliations

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

Authors

Affiliations

Conflict of interest statement

Comment in

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical